Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B
Micheline C. Chu(Columbia University), Rogerio A. Løbo(Columbia University Irving Medical Center), Enrico Carmina(OHB (Italy)), Jeff Wang(Hokkaido University)
Cited by 33
Related Papers
Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group
|Fertility and Sterility|2011|2k
Polycystic ovary syndrome
|Nature Reviews Disease Primers|2016|1.9k
American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1
|Endocrine Practice|2015|628
Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is Associated with Significant Morbidity in Women
|The Journal of Clinical Endocrinology & Metabolism|1999|508